Supernus Q2 FY26 net loss widens to $58.4 million; revenue rises 32% to $219.1 million

Reuters2026/08/03 10:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Supernus posted Q2 2026 revenue of USD 219.1 million, up 32% from a year earlier.
GAAP results swung to a net loss of USD 58.4 million, or USD 1.01 per share.
GAAP operating loss widened to USD 58 million due to a non-cash USD 54.9 million APOKYN intangible impairment charge.
Growth products drove results, with Qelbree net sales rising 15% to USD 89.2 million; ONAPGO net sales were USD 13.5 million.
2026 revenue guidance was raised to USD 860 million-USD 890 million; an all-stock merger of equals with Indivior was announced.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030635PRIMZONEFULLFEED9802259) on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Supernus Q2 FY26 net loss widens to $58.4 million; revenue rises 32% to $219.1 million

You may also like

Crypto prices